- Home
- CRVO vs NRXS Comparison
CRVO vs NRXS Comparison
Compare CRVO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRVO | NRXS |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 46.3M |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CRVO | NRXS |
|---|---|---|
| Price | $4.00 | $5.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $21.50 | $8.00 |
| AVG Volume (30 Days) | 79.7K | ★ 90.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,737,974.00 | $2,685,925.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $146.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 36.29 | 9.18 |
| 52 Week Low | $1.92 | $1.33 |
| 52 Week High | $16.50 | $6.20 |
Technical Indicators
Market Signals| Indicator | CRVO | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 32.65 | 69.38 |
| Support Level | N/A | $2.28 |
| Resistance Level | $5.44 | $6.20 |
| Average True Range (ATR) | 0.43 | 0.47 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 23.35 | 91.35 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).